Orforglipron + B6 36mg

Oral capsule: Swallow intact with water, with or without food. Administer at the same time each day. No fasting requirement. Do not crush, split, or chew the capsule. At this dose, consistency of administration timing is important to maintain stable steady-state plasma concentrations.

The 36 mg dose is the highest-tier maintenance dose in this compounded series and should only be reached after successful tolerability at all preceding dose steps.

• Use context: Reserved for patients who have completed the titration sequence and for whom the prescriber has determined the 36 mg dose as the appropriate therapeutic target.
• Pyridoxine (B6): Prescriber-specified dose, included to manage residual nausea at the highest dose tier.
• All prescribing decisions — including appropriateness of the 36 mg dose, continuation, and dose adjustment — are made solely by the prescriber.

• Orforglipron: At 36 mg, produces high-level GLP-1 receptor occupancy, driving robust glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and CNS-mediated appetite and satiety modulation. The small-molecule pharmacophore enables consistent oral bioavailability and predictable receptor engagement without the injection-site or DPP-4 degradation considerations of peptide-based GLP-1 analogues.
• Pyridoxine (B6): Antiemetic cofactor; attenuates serotonin-mediated nausea pathways, particularly relevant at higher GLP-1R agonist exposures where GI adverse effects are more frequent.

Indications context: The 36 mg compounded orforglipron + B6 capsule is targeted to adults with obesity or overweight with weight-related comorbidities, or type 2 diabetes mellitus, who have completed titration and are maintained on the highest dose tier for sustained metabolic and weight management benefit. Clinical response (≥5–10% body weight loss or HbA1c reduction) should be assessed to confirm ongoing therapeutic appropriateness.

Prescriber monitoring considerations:

• Periodic HbA1c, fasting glucose, and body weight; reassess clinical benefit and continued need at least annually.
• Ongoing renal function monitoring — GI adverse effects (even at maintenance) can cause volume depletion.
• Lipase monitoring if abdominal symptoms develop.
• Bone health and nutritional status in patients with significant weight loss (>15–20% body weight).
• Cardiovascular monitoring — GLP-1R agonists have demonstrated CV benefit in peptide analogues; data for orforglipron are evolving.
• Reassess the contribution of pyridoxine at stable maintenance dose; adjust per prescriber judgment.

Contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC) or MEN2
• Known hypersensitivity to orforglipron or any formulation component

Warnings & Precautions:

• Thyroid C-cell tumors: class GLP-1R agonist warning; human clinical significance not established
• Acute pancreatitis: discontinue and evaluate if severe abdominal pain occurs
• Acute gallbladder disease: risk of cholelithiasis with significant weight loss and GLP-1R agonism; evaluate biliary symptoms
• GI adverse effects: may persist or recur at highest dose; nausea, vomiting, diarrhea — monitor for dehydration and AKI
• Gastroparesis: avoid or use with extreme caution in patients with documented delayed gastric emptying
• Drug absorption: high-dose GLP-1R agonism significantly delays gastric emptying, affecting absorption of multiple oral medications

Drug Interactions:

• Insulin/sulfonylureas: hypoglycemia risk increases at higher GLP-1R agonist doses — adjust secretagogue dosing
• Narrow therapeutic index drugs (warfarin, thyroid hormone, cyclosporine): monitor carefully for absorption changes
• Oral contraceptives: monitor for altered efficacy due to gastric emptying delay

Common Side Effects: Nausea, vomiting, diarrhea, constipation, abdominal discomfort, decreased appetite, fatigue, and eructation. GI adverse events are most prevalent at high doses; pyridoxine is included to attenuate nausea.

Store at controlled room temperature (20–25°C / 68–77°F), protected from light and moisture, in the original dispensing container. Do not refrigerate or freeze unless specified on the label. The beyond-use date assigned by Genesis Compounding appears on the label. Keep out of reach of children and discard after the beyond-use date.

How do I know if 36 mg is working?

Your prescriber will assess response by tracking weight loss (target: ≥5–10% body weight reduction from baseline) and, in diabetes, by monitoring HbA1c and fasting glucose. Subjective measures like reduced hunger, improved satiety, and dietary habit change are also meaningful markers discussed at follow-up visits.

Are there more side effects at the highest dose?

Higher GLP-1R agonist doses are associated with greater frequency of GI adverse effects, particularly nausea. Pyridoxine is co-formulated to help manage this. Most patients who have successfully titrated to 36 mg have already adapted to GLP-1R agonist GI effects at lower doses. Report any persistent or severe GI symptoms to your prescriber.

How does this compare to the injectable GLP-1 medications?

Orforglipron activates the same GLP-1 receptor as injectable agents (semaglutide, liraglutide, tirzepatide) but is taken as a daily oral capsule — no injection required. As a small molecule, it is orally bioavailable, stable at room temperature, and does not require the specialized formulation conditions of oral semaglutide.

What happens if I miss a dose?

If you miss a dose, take it as soon as you remember on the same day. If you do not remember until the next day, skip the missed dose and resume your regular schedule. Do not double up. Contact your prescriber if you miss multiple doses.

Is this FDA-approved?

Orforglipron received FDA approval in April 2026. This 36 mg + B6 compounded capsule is a prescriber-directed, patient-specific 503A preparation by Genesis Compounding and is not FDA-approved as a compounded product.